It competes with p-aminobenzoic acid for dihydrofolate synthase, hindering bacterial synthesis of dihydrofolate; when used in combination with trimethoprim and sulfadiazine, it enhances the antibacterial effect and reduces drug-resistant strains

It competes with p-aminobenzoic acid for dihydrofolate synthase, hindering bacterial synthesis of dihydrofolate; when used in combination with trimethoprim and sulfamethoxazole, it enhances the antibacterial effect and reduces drug-resistant strains

By inhibiting bacterial dihydrofolate reductase, it prevents dihydrofolate from being reduced to tetrahydrofolate; when used in combination with sulfamethoxazole and sulfadiazine, it enhances the antibacterial effect and reduces drug-resistant strains

This product is a blood lipid regulating drug of clofibric acid derivatives. It reduces blood low-density lipoprotein, cholesterol and triglycerides by inhibiting the production of very low-density lipoprotein and triglycerides and increasing their catabolism at the same time; it also increases the production of apolipoprotein A1 and A11, thereby increasing high-density lipoprotein. This product also has the effect of reducing blood uric acid in normal people and patients with hyperuricemia. Animal experiments have shown that fenofibrate is teratogenic and carcinogenic.

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. It has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus aureus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. Rifampicin also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis.